These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 30158203)

  • 21. IQOS - a heat-not-burn (HnB) tobacco product - chemical composition and possible impact on oxidative stress and inflammatory response. A systematic review.
    Kopa PN; Pawliczak R
    Toxicol Mech Methods; 2020 Feb; 30(2):81-87. PubMed ID: 31532297
    [No Abstract]   [Full Text] [Related]  

  • 22. Prevalence and patterns of tobacco and/or nicotine product use in Japan (2017) after the launch of a heated tobacco product (
    Afolalu EF; Langer P; Fischer K; Roulet S; Magnani P
    F1000Res; 2021; 10():504. PubMed ID: 35528952
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of IQOS introduction on Philip Morris International cigarette sales in Spain: a Logarithmic Mean Divisa Index decomposition approach.
    Golpe AA; Martín-Álvarez JM; Galiano A; Asensio E
    Gac Sanit; 2022; 36(4):293-300. PubMed ID: 35219532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Young Adult Correlates of IQOS Curiosity, Interest, and Likelihood of Use.
    Phan L; Strasser AA; Johnson AC; Villanti AC; Niaura R; Rehberg K; Mays D
    Tob Regul Sci; 2020 Mar; 6(2):81-90. PubMed ID: 34504901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exposure to the heated tobacco product IQOS generates apoptosis-mediated pulmonary emphysema in murine lungs.
    Nitta NA; Sato T; Komura M; Yoshikawa H; Suzuki Y; Mitsui A; Kuwasaki E; Takahashi F; Kodama Y; Seyama K; Takahashi K
    Am J Physiol Lung Cell Mol Physiol; 2022 May; 322(5):L699-L711. PubMed ID: 35380471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A six-month systems toxicology inhalation/cessation study in ApoE
    Phillips B; Szostak J; Titz B; Schlage WK; Guedj E; Leroy P; Vuillaume G; Martin F; Buettner A; Elamin A; Sewer A; Sierro N; Choukrallah MA; Schneider T; Ivanov NV; Teng C; Tung CK; Lim WT; Yeo YS; Vanscheeuwijck P; Peitsch MC; Hoeng J
    Food Chem Toxicol; 2019 Apr; 126():113-141. PubMed ID: 30763686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perceived relative harm of heated tobacco products (IQOS), e-cigarettes, and cigarettes among adults in Canada: Findings from the ITC Project.
    Sutanto E; Miller CR; Smith DM; O'Connor RJ; Gravely S; Hammond D; Hyland A; Cummings KM; Quah ACK; Fong GT; Agar TK; Goniewicz ML
    Tob Induc Dis; 2020; 18():81. PubMed ID: 33013277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic exposure to IQOS results in impaired pulmonary function and lung tissue damage in mice.
    Gu J; Gong D; Wang Y; Feng T; Zhang J; Hu S; Min L
    Toxicol Lett; 2023 Feb; 374():1-10. PubMed ID: 36462770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IQOS debut in the USA: Philip Morris International's heated tobacco device introduced in Atlanta, Georgia.
    Churchill V; Weaver SR; Spears CA; Huang J; Massey ZB; Fairman RT; Pechacek TF; Ashley DL; Popova L
    Tob Control; 2020 Dec; 29(e1):e152-e154. PubMed ID: 32024772
    [No Abstract]   [Full Text] [Related]  

  • 30. Acute Effects of a Heat-Not-Burn Tobacco Product on Pulmonary Function.
    Pataka A; Kotoulas S; Chatzopoulos E; Grigoriou I; Sapalidis K; Kosmidis C; Vagionas A; Perdikouri ΕI; Drevelegas K; Zarogoulidis P; Argyropoulou P
    Medicina (Kaunas); 2020 Jun; 56(6):. PubMed ID: 32545573
    [No Abstract]   [Full Text] [Related]  

  • 31. Marketing IQOS in a dark market.
    Mathers A; Schwartz R; O'Connor S; Fung M; Diemert L
    Tob Control; 2019 Mar; 28(2):237-238. PubMed ID: 29724866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased oxidative stress and effects on inflammatory cytokine secretion by heated tobacco products aerosol exposure to mice.
    Sawa M; Ushiyama A; Inaba Y; Hattori K
    Biochem Biophys Res Commun; 2022 Jun; 610():43-48. PubMed ID: 35462100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute Effects of Heated Tobacco Product (IQOS) Aerosol Inhalation on Lung Tissue Damage and Inflammatory Changes in the Lungs.
    Bhat TA; Kalathil SG; Leigh N; Muthumalage T; Rahman I; Goniewicz ML; Thanavala YM
    Nicotine Tob Res; 2021 Jun; 23(7):1160-1167. PubMed ID: 33346355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of IQOS introduction on cigarette sales: evidence of decline and replacement.
    Stoklosa M; Cahn Z; Liber A; Nargis N; Drope J
    Tob Control; 2020 Jul; 29(4):381-387. PubMed ID: 31209129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IQOS Marketing in the US: The Need to Study the Impact of FDA Modified Exposure Authorization, Marketing Distribution Channels, and Potential Targeting of Consumers.
    Berg CJ; Abroms LC; Levine H; Romm KF; Khayat A; Wysota CN; Duan Z; Bar-Zeev Y
    Int J Environ Res Public Health; 2021 Oct; 18(19):. PubMed ID: 34639851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Philip Morris advertisement for its heated tobacco product IQOS sets a troubling precedent.
    Leas EC; Cohen JE; Ayers JW
    Tob Control; 2020 Dec; 29(e1):e168-e170. PubMed ID: 32019894
    [No Abstract]   [Full Text] [Related]  

  • 37. Cigarettes with defective filters marketed for 40 years: what Philip Morris never told smokers.
    Pauly JL; Mepani AB; Lesses JD; Cummings KM; Streck RJ
    Tob Control; 2002 Mar; 11 Suppl 1(Suppl 1):I51-61. PubMed ID: 11893815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Awareness and interest in IQOS heated tobacco products among youth in Canada, England and the USA.
    Czoli CD; White CM; Reid JL; OConnor RJ; Hammond D
    Tob Control; 2020 Jan; 29(1):89-95. PubMed ID: 30696783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Household Surveys in the General Population and Web-Based Surveys in IQOS Users Registered at the Philip Morris International IQOS User Database: Protocols on the Use of Tobacco- and Nicotine-Containing Products in Germany, Italy, and the United Kingdom (Greater London), 2018-2020.
    Sponsiello-Wang Z; Langer P; Prieto L; Dobrynina M; Skiada D; Camille N; Weitkunat R; Lüdicke F
    JMIR Res Protoc; 2019 May; 8(5):e12061. PubMed ID: 31094340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of FDA's IQOS marketing authorisation and its policy impacts.
    Lempert LK; Glantz S
    Tob Control; 2020 Jun; ():. PubMed ID: 32601147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.